Stapedotomy — Laser-Assisted Small Fenestra Stapes Surgery for Otosclerosis — Cost, Top Hospitals & Success Rates | MyMedicPlus

Stapedotomy is the current gold-standard surgical treatment for otosclerosis-induced conductive hearing loss. Unlike the classic stapedectomy — in which the entire stapes (including its footplate) is removed — stapedotomy involves creating a small fenestra (hole) in the stapes footplate, through which a precisely sized prosthetic piston is inserted to re-establish the sound-transmitting chain between the incus and the inner ear. The footplate itself is preserved, providing a stable platform and maintaining the integrity of the bony labyrinthine capsule.

The laser-assisted variant — known as LASSH (Laser-Assisted Stapedotomy Sur Sautey-Hermann), or more generally as laser stapedotomy — uses laser energy (KTP 532 nm, diode 810/980 nm, or CO2 10,600 nm) to create the fenestra with extreme precision and negligible mechanical trauma to the underlying perilymph and membranous labyrinth. The laser vaporises or ablates the footplate bone in a controlled 0.4–0.8 mm circular spot, largely eliminating the mechanical forces that can cause perilymph disruption, sensorineural hearing loss, or floating footplate — the major hazards of hand-instrument footplate perforation.

Stapedotomy was developed from the foundational work of Hans Fisch in Zurich (small-fenestra stapedotomy, 1980s) and refined with laser technology through the contributions of Lesinski, Perkins, and Verneuil. The standard fenestra diameter in most contemporary centres is 0.6 mm — matched to the shaft diameter of the Teflon or fluoroplastic piston used. Smaller fenestrae (0.4 mm) have been advocated for maximal perilymph preservation; larger ones (0.8 mm) for obliterative disease or thick footplates.

Modern series consistently demonstrate that laser stapedotomy achieves superior audiometric outcomes compared to classic stapedectomy in uncomplicated otosclerosis, with higher rates of air-bone gap closure to ≤10 dB and lower rates of sensorineural hearing loss, establishing it as the preferred first-line surgical technique at high-volume stapes centres worldwide.

Stapedotomy addresses several variants of stapes pathology, ranging from straightforward to complex:

• Fenestral otosclerosis (classic type): Spongiotic bone at the fissula ante fenestram (anterior oval window niche) progressively fixes the anterior footplate, reducing stapes mobility. This is the most common pattern and the ideal indication for laser stapedotomy — the footplate is of normal thickness, allowing precise laser fenestration without risk of diving or fracture.
• Diffuse or obliterative otosclerosis: Advanced disease replacing the entire footplate with thick, vascular, spongiotic bone ("biscuit footplate" on high-resolution CT). The thickened footplate requires higher laser energy or mechanical drilling with a microdrill before fenestration is achievable. Stapedotomy in obliterative disease is technically demanding; some surgeons prefer total footplate removal (stapedectomy) in this setting. Obliterative otosclerosis has been associated with NF2 gene mutations in some case series, particularly in bilateral juvenile-onset disease.
• Floating footplate: A complication during any footplate manipulation in which the footplate becomes detached from the annular ligament and sinks into the vestibule. Laser stapedotomy significantly reduces floating footplate risk compared to hand-instrument techniques by avoiding shear forces. If floating occurs, the prosthesis can sometimes still be placed through the fenestra if the footplate is stabilised; retrieval of a deeply sunken footplate risks catastrophic SNHL and is generally avoided.
• Bilateral otosclerosis: Present in ~70% of affected patients. Sequential bilateral stapedotomy is the treatment of choice for bilateral disease, eliminating or reducing hearing aid dependence. The worse-hearing ear is typically operated first, with the second ear addressed 6–12 months later if the first is successful.
• Revision stapes surgery (selected cases): Stapedotomy with laser can address prosthesis displacement, incus long-process necrosis, or fibrotic re-obliteration of the fenestra in previously operated cases, though revision surgery carries higher risks than primary surgery.

Eligibility criteria for stapedotomy are essentially the same as for stapedectomy, with some additional considerations related to footplate morphology:

• Audiometric criteria: An air-bone gap ≥30 dB at two or more frequencies, demonstrating clinically significant conductive hearing loss. Bone conduction thresholds (cochlear reserve) should be ≤35 dB HL in speech frequencies to ensure functional gain from surgery.
• Diagnosis of stapes fixation: Confirmed by tympanometry (flat type A (As) tympanogram with reduced compliance), acoustic reflex absence, and audiometric findings consistent with conductive hearing loss. High-resolution CT of the temporal bone is performed for obliterative disease, revision cases, or suspected inner ear anomaly, to delineate footplate thickness, identify abnormal facial nerve course, and exclude cochlear malformations predisposing to perilymph gusher.
• Footplate morphology: High-resolution CT guides surgical planning. A normal-thickness footplate (0.2–0.4 mm) is ideal for laser stapedotomy. Thick obliterative footplates (>1 mm) may require a modified approach. A "halo sign" of cochlear otosclerosis around the basal turn of the cochlea on CT predicts sensorineural involvement and may temper the patient's audiometric expectations.
• Exclusion of X-linked stapes gusher: Males with disproportionately severe conductive hearing loss, family history of similar hearing loss, and CT showing dilation of the lateral end of the internal auditory canal (fundus defect or bulging) should be suspected of DFNX2/POU3F4 mutation. Stapedotomy in this condition carries a very high risk of profuse gusher and devastating SNHL; bone-anchored hearing devices are the safer alternative.
• Medical fitness: Patients with active otitis media, chronic ear disease, or Eustachian tube dysfunction require pre-operative treatment before stapes surgery. Anticoagulant medications are managed perioperatively per anaesthetic protocol.

The choice of laser and prosthesis in stapedotomy is nuanced and influenced by surgeon training, equipment availability, and footplate characteristics:

• KTP (potassium titanyl phosphate, 532 nm) laser: The most widely used laser for stapedotomy. Green-wavelength light is well absorbed by vascular spongiotic bone and haemoglobin, providing precise ablation with minimal thermal spread. The KTP laser can be delivered via a handpiece or through the operating microscope using a micromanipulator. It can also seal the incudostapedial joint and divide the posterior crus bloodlessly. Limitation: less effective on purely white (avascular) footplates.
• Diode laser (810 or 980 nm): Near-infrared; absorbed by melanin and haemoglobin. Compact, portable, and lower cost than KTP. Delivered via optical fibre through a handpiece. Growing in popularity for stapedotomy due to good haemostatic properties and versatility in obliterative disease.
• CO2 laser (10,600 nm): Far-infrared; absorbed by water in all biological tissues, including avascular white footplate bone. The original stapedotomy laser (Perkins, 1980). Does not require tissue pigmentation for absorption, making it superior for avascular or calcified footplates. Delivered via micromanipulator (CO2 cannot be transmitted through optical fibres) — requires coupling to the operating microscope, limiting flexibility.
• Fenestra creation: Laser shots (typically 3–6 single pulses) are applied in a rosette pattern to create a 0.6-mm circular fenestra. The surgeon uses a calibrated measuring rod to confirm diameter. A right-angle hook gently enlarges the fenestra if necessary before prosthesis insertion.
• Prosthesis types: The Lippy-Robinson piston (Teflon with malleable stainless steel or gold wire hook) is a widely used design; the hook is crimped around the incus long process with a hook crimper or automatised with Nitinol self-crimping technology. Other common prostheses: Fisch-type Teflon piston, titanium Kurz prosthesis, and GYRUS/Medtronic Flex piston. Piston shaft diameter matches the fenestra (0.4, 0.5, 0.6, or 0.8 mm). Length is measured from the incus long process to the footplate surface and typically 4.0–4.75 mm for most adults.
• Perilymph seal: Unlike stapedectomy, the small fenestra created in stapedotomy acts as its own watertight fit around the piston shaft — no tissue graft seal is required in most cases, which is an additional advantage of the small-fenestra technique in eliminating graft-related complications.

Laser stapedotomy offers several advantages over both classic stapedectomy and non-surgical hearing rehabilitation:

• Superior audiometric outcomes: Large published series (Vincent et al., 2002; Marchese et al.; Wegner) demonstrate ABG closure to ≤10 dB in 80–85% of laser stapedotomy cases — matching or exceeding classic stapedectomy outcomes, while delivering lower SNHL rates.
• Reduced sensorineural hearing loss risk: By preserving the footplate architecture and eliminating shear forces on the perilymph, laser stapedotomy reduces profound SNHL risk to approximately 1–1.5% compared to 1–2% for stapedectomy in standard cases — a meaningful advantage when multiplied over thousands of cases annually.
• Lower perilymph gusher risk: The controlled fenestra created by laser pulses carries negligible risk of sudden footplate displacement or perilymph flooding compared to hand-instrument perforation or footplate fragmentation.
• No tissue graft required: Eliminating the seal tissue graft simplifies the procedure, shortens operating time, and removes the small risk of graft resorption, granuloma, or fibrotic obliteration of the oval window.
• Bloodless field: Laser haemostasis during incudostapedial joint division and posterior crural fracture provides a clear surgical field, reducing the need for irrigation and improving precision.
• Outpatient procedure: Laser stapedotomy is performed as a day-case procedure under local anaesthesia in most adults, allowing immediate hearing testing (patient reports hearing the surgeon's voice when the piston is placed) and rapid discharge without overnight hospital admission.

While stapedotomy is one of the safer middle ear surgical procedures, specific complications must be discussed with patients:

• Sensorineural hearing loss: Despite the inherent advantages of the small-fenestra laser technique, sensorineural hearing loss remains the most serious complication, occurring as profound loss in ~1–1.5% and as a mild-to-moderate loss in a further 3–4%. Causes include acoustic trauma from laser energy (CO2 laser has the least thermal spread; KTP the most haemostatic), mechanical trauma during prosthesis seating, and perilymph fistula from an over-large fenestra.
• Floating footplate: Even with laser technique, the footplate can become detached (though less commonly than with hand instruments), sinking into the vestibule. The response is determined by position — if the footplate floats anteriorly and the fenestra is accessible, prosthesis placement may proceed; retrieval of a posteriorly sunken footplate is hazardous and generally not attempted.
• Prosthesis displacement: The piston can migrate out of the fenestra (over-long prosthesis pressing on the saccule) or out of the incus hook (under-crimped wire). Both cause hearing loss and may cause vertigo. Revision surgery is required.
• Taste disturbance: Chorda tympani stretching or division causes anterior tongue taste alteration in 20–30% of patients; permanent disturbance in 5–10%. Dry mouth and metallic taste are described. Patients should be warned pre-operatively, particularly if the contralateral chorda has been compromised in prior surgery.
• Obliterative otosclerosis-specific risks: Thick, vascular footplates require higher laser energy or supplemental mechanical drilling, increasing thermal exposure to the inner ear. Haemorrhage into the vestibule from highly vascular spongiotic bone is a risk; adrenaline-soaked gelfoam pledgets are placed pre-operatively to reduce vascularity.
• Tinnitus: Pre-existing tinnitus improves in the majority of successful cases but can paradoxically persist or worsen, particularly if any degree of sensorineural loss occurs post-operatively.

Post-operative care for stapedotomy is similar to stapedectomy, with some important nuances:

• Immediate recovery: Patients are typically discharged on the day of surgery. Mild vertigo for 24–48 hours is expected as the inner ear equilibrates to the new piston. Anti-emetics (ondansetron) and vestibular sedatives (cinnarizine) are prescribed for the first 48 hours. Sudden severe vertigo or new profound hearing loss warrants urgent review.
• Activity restrictions: Nose-blowing is strictly prohibited for 3 weeks. Air travel is avoided for 6 weeks. Strenuous exercise, heavy lifting, and bending forwards are restricted for 3 weeks to prevent Valsalva-induced perilymph fistula at the new fenestra site.
• Audiometric review at 6–8 weeks: Pure tone audiogram (air and bone conduction at 250–8,000 Hz) and speech discrimination testing confirm the hearing result. An ABG of ≤10 dB at two or more frequencies indicates surgical success. Speech audiometry helps quantify functional hearing gain in noisy environments.
• Annual audiometry: Annual pure tone audiograms for the first 5 years, then every 2–3 years. Late hearing deterioration requires differentiation between: (1) incus long-process necrosis (revision surgery); (2) prosthesis displacement (revision); (3) progression of cochlear otosclerosis (hearing aid or cochlear implant); or (4) presbyacusis (amplification).
• Bilateral disease sequencing: When surgery on the first ear is confirmed successful at the 6-week audiogram and the patient has recovered fully, planning for the contralateral ear can begin. A minimum 6-month interval between ears is standard practice at most centres.
• Fluoride therapy for cochlear involvement: Where high-resolution CT or audiometry indicates cochlear otosclerosis, sodium fluoride (20 mg bd) or bisphosphonates may be discussed as adjunctive therapy to retard progression of sensorineural hearing loss. The evidence base remains modest and the treatment remains controversial; patients should be informed that this does not reverse sensorineural loss already established.

Laser stapedotomy costs more than conventional hand-instrument stapedectomy due to the additional equipment required, but remains one of the most cost-effective hearing rehabilitation interventions when measured over a lifetime:

• Laser equipment costs: KTP, diode, and CO2 lasers coupled to operating microscopes represent a capital investment of USD 50,000–200,000 for the ENT department. These costs are reflected in procedure fees at laser-equipped centres. Not all ENT units have laser capability; patients seeking laser stapedotomy may need to travel to a specialist centre.
• Prosthesis costs: Basic Teflon pistons cost USD 20–100. Nitinol self-crimping prostheses (eliminating crimping forceps skill) cost USD 300–600. Titanium prostheses are intermediate in cost. In developed-country health systems, prosthesis cost represents a relatively minor component of total procedure cost.
• Country-specific pricing: India: INR 50,000–1,50,000 (USD 600–1,800) at private tertiary ENT centres including laser facility. UK (NHS): Free on referral; private: GBP 3,500–6,000. USA: USD 8,000–18,000. Germany: EUR 6,000–10,000. Singapore: SGD 8,000–14,000. India offers excellent value for international patients given the high volume of stapes surgery performed in centres such as AIIMS, Amrita, and major Apollo/Fortis hospitals.
• Lifetime cost comparison with hearing aids: High-quality hearing aids for bilateral otosclerosis: USD 2,000–8,000 per pair, with 5-year replacement cycles and annual maintenance. Over 30 years, cumulative hearing aid cost substantially exceeds bilateral stapedotomy cost — making surgery the more cost-effective intervention for eligible patients in the absence of surgical contraindications.
• Insurance coverage: Stapedotomy for otosclerosis is covered by most national health systems (NHS, Medicare/Medicaid, European social insurance) and private health insurers when audiometric criteria are met and medical necessity is documented.

For patients who are not surgical candidates, who prefer to avoid surgery, or in whom stapedotomy has not achieved the desired outcome, several effective alternatives exist:

• Conventional hearing aids: The principal non-surgical alternative. Modern behind-the-ear (BTE), receiver-in-canal (RIC), and completely-in-canal (CIC) digital hearing aids provide excellent amplification for the conductive hearing loss of otosclerosis, which typically shows a flat or low-frequency audiogram pattern well-suited to hearing aid fitting. Real-ear measurement ensures appropriate gain prescription. Hearing aids avoid all surgical risks and are fully reversible. They are the first-line recommendation for patients with a single functioning ear, those with medical contraindications to surgery, or those who prefer a non-invasive approach.
• Bone-anchored hearing aids (BAHA): An osseointegrated titanium implant (Cochlear Baha, Oticon Medical Ponto, MED-EL Osia) transmits sound via direct bone conduction to the cochlea. BAHA is particularly effective for bilateral conductive hearing loss, avoiding the need for conventional ear canal-based amplification. A soft-band trial is available for hearing assessment before surgical implantation. The Osia 2 active transcutaneous system offers magnetic coupling without a percutaneous abutment.
• Stapedectomy (total footplate removal): For obliterative otosclerosis where laser fenestration is not technically feasible or has failed, total footplate removal with tissue graft seal remains a valid alternative. Modern ablative drills (skeeter drill, micromotor) allow controlled total footplate removal even in thick obliterative disease.
• Cochlear implantation: In advanced bilateral cochlear otosclerosis with profound sensorineural hearing loss (beyond hearing aid benefit), cochlear implantation provides the best rehabilitation. High-resolution CT pre-operatively identifies cochlear ossification and guides electrode selection (standard full-length or compressed arrays for partial obliteration).
• Fluoride therapy (sodium fluoride/bisphosphonates): Sodium fluoride 20 mg twice daily, or alendronate 10 mg daily, inhibits osteoclast-mediated bone remodelling and has been advocated to retard cochlear otosclerosis progression. Evidence is inconclusive; a Cochrane review found insufficient high-quality trial data to support routine use. It is occasionally used as an adjunct in patients with active cochlear disease (positive CT halo sign) to complement stapedotomy or hearing aid rehabilitation.
• Middle ear implants (MEI): Active implantable devices (MED-EL Vibrant Soundbridge, Cochlear Codacs) couple directly to the ossicular chain or oval window, providing amplification without occluding the ear canal. Used for mixed hearing loss or in patients with ear canal problems precluding conventional aids; an emerging option for otosclerosis when stapes surgery is declined.